NASH-TAG (Therapeutic Agents for Non-Alcoholic Steatohepatitis and Liver Fibrosis) Conference 2019
Event Date: January 3 - 5, 2019
Event Location: The Chateaux Deer Valley, 7815 Royal Street East, Park City, UT 84060
Diapharma will attend NASH-TAG 2019 this year. Please click here to schedule a meeting with us or email us directly.
Learn from the leading researchers in NASH and Liver Fibrosis at NASH-TAG 2019
NASH-TAG = THERAPEUTIC AGENTS for NON-ALCOHOLIC STEATOHEPATITIS
About NASH-TAG
The NASH-TAG Conference is designed to bring together clinicians and researchers in academia and the pharmaceutical industry for a focused interactive educational update highlighting the most relevant advances and challenges in the diagnosis and therapy of NASH and liver fibrosis. NASH-TAG 2019 will take place over two days providing attendees an understanding of current and future directions in diagnostic procedures, prospects and challenges in drug discovery and development for both NASH and liver fibrosis. Internationally renowned faculty will assist in the development of the educational content and will serve as faculty at the conference.
NASH-TAG Topics will include
- MGL 3196 – a beta thyroid hormone receptor selective agonist
- Aramchol – SCD1 modulator
- NGM 282 – FGF19 construct
- GS 9674 FXR – second generation FXR agonist
- Selective PPAR modulators, hepatic and metabolic effects
- Interactive Dialog on NASH Topics
- Mitochrnodrial uncoupling as a pharmacological target in NASH
- Extracellular vesticles as mediators of inflammation
- Singnals form peclinical models and success of NASH trials
- 3D Trissue modeling and precision cut liver slices: Will they help drug testing for NASH?
- Barriers to overcome for reimbursement of NASH drugs
- Lessons learned fromt he reimbursement of diabetes and CV drugs
- Forecasting how the NASH market will develop in the US
- Pros in clinical trials of NASH
- Current and future trends in hepatic MRI using a background of cardiac MRI development
- Assessing DILI in NASH trials
- Genetic testing: Any use of sub phenotyping or risk stratification in clinical trials?
- Update from EASL & AASLD
- Understanding the methods of and need for CV risk assessment
- Second harmonic generation fully quantitative histopathology assessment for NASH
- GLP1R agonist compounds
- GLP1 – glucagon receptor dual agonists
- FGF21 – GLP1 dual agonism
- Integrin antgonism as an anti-fibrotoic therapy
- GPR40 and 84G cell coupled receptor modulators, BPI-4050
- P2x7 – puringergic receptor antagoist
NASH-TAG | Facebook | Twitter | LinkedIn | The Chateaux Deer Valley